Articles dans des revues avec comité de lecture (78)
  1. 15. Pavord, I. D., Bel, E., Bourdin, A., Chan, R., Han, J. J., Keene, O. O., Liu, M. M., Martin, N., Papi, A., Roufosse, F., Steinfeld, J., Wechsler, M. M., & Yancey, S. S. (2021). From DREAM to REALITI-A and beyond: Mepolizumab for the treatment of eosinophil-driven diseases. Allergy, 10.1111/all.15056, 34402066. doi:10.1111/all.15056
  2. 16. Bondue, A., Carpentier, C., & Roufosse, F. (2021). Hypereosinophilic syndrome: Considerations for the cardiologist. Heart, 10.1136/heartjnl-2020-317202, 317202. doi:10.1136/heartjnl-2020-317202
  3. 17. Carpentier, C., Verbanck, S., Schandené, L., Heimann, P., Trepant, A.-L., Cogan, E., & Roufosse, F. (2020). Eosinophilia Associated With CD3−CD4+ T Cells: Characterization and Outcome of a Single-Center Cohort of 26 Patients. Frontiers in immunology, 11, 1765. doi:10.3389/fimmu.2020.01765
  4. 18. Brenard, E., Pilette, C., Dahlqvist, C., Colinet, B., Schleich, F. N. I. F., Roufosse, F., & Froidure, A. (2020). Real-Life Study of Mepolizumab in Idiopathic Chronic Eosinophilic Pneumonia. Lung, 198(2), 355-360. doi:10.1007/s00408-020-00336-3
  5. 19. Roufosse, F., Kahn, J.-E., Rothenberg, M., Wardlaw, A., Klion, A., Kirby, S. Y., Gilson, M. M., Bentley, J. J., Bradford, E. E., Yancey, S. S., Steinfeld, J., & Gleich, G. (2020). Efficacy and safety of mepolizumab in hypereosinophilic syndrome: A phase III, randomized, placebo-controlled trial. Journal of allergy and clinical immunology. doi:10.1016/j.jaci.2020.08.037
  6. 20. Silva, M., & Roufosse, F. (2019). Oral Corticosteroid Use for the Treatment of Chronic Eosinophilic Disease: A Patient’s and His Physician’s Experience. Advances in therapy, 36(10), 2558-2566. doi:10.1007/s12325-019-01070-w
  7. 21. Khoury, P., Akuthota, P., Ackerman, S. S., Arron, J. J., Bochner, B. B., Collins, M. M., Kahn, J.-E., Fulkerson, P. P., Gleich, G. G., Gopal-Srivastava, R., Jacobsen, E. E., Leiferman, K., Francesca, L. S., Mathur, S. S., Minnicozzi, M., Prussin, C., Rothenberg, M., Roufosse, F., Sable, K., Simon, D., Simon, H.-U., Spencer, L. L., Steinfeld, J., Wardlaw, A., Wechsler, M. M., Weller, P., & Klion, A. (2018). Revisiting the NIH Taskforce on the Research needs of Eosinophil-Associated Diseases (RE-TREAD). Journal of leukocyte biology, 104(1), 69-83. doi:10.1002/JLB.5MR0118-028R
  8. 22. Roufosse, F. (2018). Targeting the interleukin-5 pathway for treatment of eosinophilic conditions other than asthma. Frontiers in Medicine, 5(APR), 49. doi:10.3389/fmed.2018.00049/full
  9. 23. Roufosse, F., & Johansson, M. M. (2018). Editorial: Pathogenic advances and therapeutic perspectives for eosinophilic inflammation. Frontiers in Medicine, 5(AUG), 00243. doi:10.3389/fmed.2018.00243
  10. 24. Wechsler, M., Akuthota, P., Jayne, D. R., Khoury, P., Klion, A., Langford, C. A., Merkel, P. P., Moosig, F., Specks, U., Cid, M. M., Luqmani, R., Brown, J., Mallett, S., Philipson, R., Yancey, S. S., Steinfeld, J., Weller, P. F., Gleich, G. J., EGPA Mepolizumab Study Team,, Roufosse, F., et al. (2017). Mepolizumab or Placebo for Eosinophilic Granulomatosis with Polyangiitis. The New England journal of medicine, 376(20), 1921-1932. doi:10.1056/NEJMoa1702079
  11. 25. Garaud, S., Roufosse, F., De Silva, P., Gu-Trantien, C., Lodewyckx, J. N., Duvillier, H., Dedeurwaerder, S., Bizet, M., Defrance, M., Fuks, F., Bex, F., & Willard-Gallo, K. (2017). FOXP1 is a regulator of quiescence in healthy human CD4+ T cells and is constitutively repressed in T cells from patients with lymphoproliferative disorders. European Journal of Immunology, 47(1), 168-179. doi:10.1002/eji.201646373
  12. 26. De Wilde, V., Roufosse, F., & Hermine, O. (2016). Clonal eosinophil and mast cell diseases: different in the same way? Expert Review of Hematology, 9(12), 1107-1109. doi:10.1080/17474086.2016.1254036
    13. << Précédent 1 2 3 4 5 6 7 8 9 Suivant >>